Preferential formation of MT1/MT2 melatonin receptor heterodimers with distinct ligand interaction properties compared with MT 2 homodimers

Molecular Pharmacology

Volumn 66, Issue 2, 2004, Pages 312-321

  Ayoub, Mohammed A ^a   Levoye, Angélique ^a   Delagrange, Philippe ^b   Jockers, Ralf ^a  

^a INSTITUT COCHIN   (France)

^b INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DIMER; G PROTEIN COUPLED RECEPTOR; HETERODIMER; HOMODIMER; MELATONIN RECEPTOR; MT1 MELATONIN RECEPTOR; MT2 MELATONIN RECEPTOR; UNCLASSIFIED DRUG; LIGAND; MELATONIN 1 RECEPTOR; MELATONIN 2 RECEPTOR;

ARTICLE; BINDING SITE; BIOLUMINESCENCE RESONANCE ENERGY TRANSFER; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; DIMERIZATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; CELL CULTURE; METABOLISM; SERODIAGNOSIS; STATISTICS;

BINDING SITES; CELLS, CULTURED; DIMERIZATION; HUMANS; LIGANDS; PRECIPITIN TESTS; RECEPTOR, MELATONIN, MT1; RECEPTOR, MELATONIN, MT2; STATISTICS;

EID: 3342965731     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.104.000398     Document Type: Article

References (42)

1. Angers S, Salahpour A, Joly E, Hilairet S, Chelsky D, Dennis M, and Bouvier M (2000) Detection of β2-adrenergic receptor dimerization in living cells using bioluminescence resonance energy transfer (BRET). Proc Natl Acad Sci USA 97:3684-3689.
2. Audinot V, Mailliet F, Lahaye-Brasseur C, Bonnaud A, Le Gall A, Amosse C, Dromaint S, Rodriguez M, Nagel N, Galizzi JP, et al. (2003) New selective ligands of human cloned melatonin MT1 and MT2 receptors. Naunyn Schmiedeberg's Arch Pharmacol 367:553-561.
3. Ayoub MA, Couturier C, Lucas-Meunier E, Angers S, Fossier P, Bouvier M, and Jockers R (2002) Monitoring of ligand-independent dimerization and ligand-induced conformational changes of melatonin receptors in living cells by bioluminescence resonance energy transfer. J Biol Chem 277:21522-21528.
4. Boute N, Pernet K, and Issad T (2001) Monitoring the activation state of the insulin receptor using bioluminescence resonance energy transfer. Mol Pharmacol 60:640-645.
5. Brydon L, Barrett P, Morgan PJ, Strosberg AD, and Jockers R (1999a) Investigation of the human Mel 1a melatonin receptor using anti-receptor antibodies. Adv Exp Med Biol 460:215-220.
6. Brydon L, Petit L, Delagrange P, Strosberg AD, and Jockers R (2001) Functional expression of MT2 (Mel1b) melatonin receptors in human PAZ6 adipocytes. Endocrinology 142:4264-4271.
7. q/11 proteins. Mol Endocrinol 13:2025-2038.
8. Couturier C and Jockers R (2003) Activation of the leptin receptor by a ligand-induced conformational change of constitutive receptor dimers. J Biol Chem 278:26604-26611.
9. Dubocovich ML (1983) Melatonin is a potent modulator of dopamine release in the retina. Nature (Lond) 306:782-784.
10. Dubocovich ML, Masana MI, Iacob S, and Sauri DM (1997) Melatonin receptor antagonists that differentiate between the human Mel1a and Mel1b recombinant subtypes are used to assess the pharmacological profile of the rabbit retina ML1 presynaptic heteroreceptor. Naunyn Schmiedeberg's Arch Pharmacol 355:365-375.
11. 125I] iodomelatonin to characterize melatonin binding sites in chicken retina. Proc Natl Acad Sci USA 84:3916-3920.
12. Farrens DL, Altenbach C, Yang K, Hubbell WL, and Khorana HG (1996) Requirement of rigid-body motion of transmembrane helices for light activation of rhodopsin. Science (Wash DC) 274:768-770.
13. Ferre S, Torvinen M, Antoniou K, Irenius E, Civelli O, Arenas E, Fredholm BB, and Fuxe K (1998) Adenosine A1 receptor-mediated modulation of dopamine D1 receptors in stably cotransfected fibroblast cells. J Biol Chem 273:4718-4724.
14. Gazi L, Lopez-Gimenez JF, and Strange PG (2002) Formation of oligomers by G protein-coupled receptors. Curr Opin Drug Discov Dev 5:756-763.
15. George SR, Fan T, Xie Z, Tse R, Tam V, Varghese G, and O'Dowd BF (2000) Oligomerization of μ- and δ-opioid receptors. Generation of novel functional properties. J Biol Chem 275:26128-26135.
16. Ghanouni P, Steenhuis JJ, Farrens DL, and Kobilka BK (2001) Agonist-induced conformational changes in the G-protein-coupling domain of the β2 adrenergic receptor. Proc Natl Acad Sci USA 98:5997-6002.
17. Hague C, Uberti MA, Chen Z, Hall RA, and Minneman KP (2004) Cell surface expression of α1D-adrenergic receptors is controlled by heterodimerization with α1B-adrenergic receptors. J Biol Chem 279:15541-15549.
18. Heyduk T (2002) Measuring protein conformational changes by FRET/LRET. Curr Opin Biotechnol 13:292-296.
19. Issafras H, Angers S, Bulenger S, Blanpain C, Parmentier M, Labbe-Jullie C, Bouvier M, and Marullo S (2002) Constitutive agonist-independent CCR5 oligomerization and antibody-mediated clustering occurring at physiological levels of receptors. J Biol Chem 277:34666-34673.
20. Jones KA, Borowsky B, Tamm JA, and Gerald C (1998) GABAb receptors function as a heterotrimeric assembly of the subunits GABAbR1 and GAGbR2. Nature (Lond) 396:674-679.
21. Jordan BA and Devi LA (1999) G-protein-coupled receptor heterodimerization modulates receptor function. Nature (Lond) 399:697-700.
22. Kenakin T and Onaran O (2002) The ligand paradox between affinity and efficacy: can you be there and not make a difference? Trends Pharmacol Sci 23:275-280.
23. B receptor is required for activation and allosteric interaction between the subunits. J Neurosci 22:7352-7361.
24. Krause DN, Barrios VE, and Duckles SP (1995) Melatonin receptors mediate potentiation of contractile responses to adrenergic nerve stimulation in rat caudal artery. Eur J Pharmacol 276:207-213.
25. Kroeger KM, Hanyaloglu AC, Seeber RM, Miles LE, and Eidne KA (2001) Constitutive and agonist-dependent homo-oligomerization of the thyrotropin-releasing hormone receptor. Detection in living cells using bioluminescence resonance energy transfer. J Biol Chem 276:12736-12743.
26. Lee J, Pilch PF, Shoelson SE, and Scarlata SF (1997) Conformational changes of the insulin receptor upon insulin binding and activation as monitored by fluorescence spectroscopy. Biochemistry 36:2701-2708.
27. Masana MI and Dubocovich ML (2001) Melatonin receptor signaling: finding the path through the dark. Sci STKE 2001:PE39.
28. McVey M, Ramsay D, Kellett E, Rees S, Wilson S, Pope AJ, and Milligan G (2001) Monitoring receptor oligomerization using time-resolved fluorescence resonance energy transfer and bioluminescence resonance energy transfer. The human δ-opioid receptor displays constitutive oligomerization at the cell surface, which is not regulated by receptor occupancy. J Biol Chem 276:14092-14099.
29. Mercier JF, Salahpour A, Angers S, Breit A, and Bouvier M (2002) Quantitative assessment of β1- and β2-adrenergic receptor homo- and heterodimerization by bioluminescence resonance energy transfer. J Biol Chem 277:44925-44931.
30. Morgan PJ, Barrett P, Howell HE, and Helliwell R (1994) Melatonin receptors: localization, molecular pharmacology and physiological significance. Neurochem Int 24:101-146.
31. Patel RC, Kumar U, Lamb DC, Eid JS, Rocheville M, Grant M, Rani A, Hazlett T, Patel SC, Gratton E, et al. (2002) Ligand binding to somatostatin receptors induces receptor-specific oligomer formation in live cells. Proc Natl Acad Sci USA 99:3294-3299.
32. 125I]iodomelatonin binding sites in Syrian hamster peripheral organs. J Pharmacol Exp Ther 290:334-340.
33. Petit L, Lacroix I, de Coppet P, Strosberg AD, and Jockers R (1999) Differential signaling of human Mella and Mellb melatonin receptors through the cyclic guanosine 3′-5′-monophosphate pathway. Biochem Pharmacol 58:633-639.
34. 2A. J Biol Chem 276:14027-14036.
35. Reppert SM, Weaver DR, Rivkees SA, and Stopa EG (1988) Putative melatonin receptors in human biological clock. Science (Wash DC) 242:78-81.
36. Rocheville M, Lange DC, Kumar U, Patel SC, Patel RC, and Patel YC (2000a) Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity. Science (Wash DC) 288:154-157.
37. Rocheville M, Lange DC, Kumar U, Sasi R, Patel RC, and Patel YC (2000b) Subtypes of the somatostatin receptor assemble as functional homo- and heterodimers. J Biol Chem 275:7862-7869.
38. i: precoupling and constitutive activity. Mol Pharmacol 56:1014-1024.
39. Terrillon S, Barberis C, and Bouvier M (2004) Heterodimerization of V1a and V2 vasopressin receptors determines the interaction with β-arrestin and their trafficking patterns. Proc Natl Acad Sci USA 101:1548-1553.
40. Terrillon S, Durroux T, Mouillac B, Breit A, Ayoub MA, Taulan M, Jockers R, Barberis C, and Bouvier M (2003) Oxytocin and vasopressin V1a and V2 receptors form constitutive homo- and heterodimers during biosynthesis. Mol Endocrinol 17:677-691.
41. Truong K and Ikura M (2001) The use of FRET imaging microscopy to detect protein-protein interactions and protein conformational changes in vivo. Curr Opin Struct Biol 11:573-578.
42. Vilardaga JP, Bunemann M, Krasel C, Castro M, and Lohse MJ (2003) Measurement of the millisecond activation switch of G protein-coupled receptors in living cells. Nat Biotechnol 21:807-812.